2024 SABCS会议预告｜12月10日有哪些精彩看点？

时间：12月10日 8:00 – 9:15 am（Central Time）（本文均为美国中央时间）

柳叶刀乳腺癌专场

Lancet Breast Cancer Session

时间：12月10日 9:30 – 11:30 am

ABC Global Alliance 与 US MBC Alliance 交流专场

ABC Global Alliance and US MBC Alliance Communication Session

地点和时间：Hemisfair Ballroom 1-2，12月10日 12:00 – 1:45 pm

主持人：Carol Fabian, University of Kansas Medical Center, Westwood, Kansas

对热量限制和体力活动反应的遗传和表观遗传变化

Genetic and Epigenetic Changes in Response to Caloric Restriction and Physical Activity 

Catherine Duggan, Fred Hutchinson Cancer Center, Seattle, Washington 

实现足够的脂肪减少和代谢改善以降低癌症风险：基于新一代GLP-1n和GIP受体激动剂（营养感知激素[NUSH]）的疗法

Achieving Sufficient Fat Loss and Metabolic Improvement to Reduce Cancer Risk: Newer Generation GLP-1n and GIP Receptor Agonists (Nutrient Sensing Hormone (NUSH) - Based Therapeutics 

Neil Iyengar, Memorial Sloan Kettering Cancer Center, New York, New York 

运动和药物治疗在减重中的作用和类型

Impact and Types of Exercise and Pharmacotherapy in Weight Loss 

John Jakicic, University of Kansas Medical Center, Westwood, Kansas 

• Panel Discussion

地点和时间：Stars at Night 3-4，12月10日 12:00 – 1:45 pm 

主持人：Laleh Amiri Kordestani, FDA, Silver Spring, Maryland, and Eric Winer, Yale University, New Haven, Connecticut. 

Patient Advocate: Victoria Goldberg, New York, New York

辅助瑞波西利

Adjuvant Ribociclib 

Jennifer Gao, FDA, Silver Spring, Maryland 

• Panel Discussion  

Inavolisib（伊那利塞）获批

Inavolisib Approval 

Suparna Wedam, FDA, Silver Spring Maryland 

• Panel Discussion 

临床试验中卵巢毒性的监测

Monitoring of Ovarian Toxicity During Clinical Trials 

Antonio Wolff, Sidney Kimmel Comprehensive Cancer Center, Baltimore,Maryland 

• Panel Discussion

地点和时间：Stars at Night 1-2，12月10日 12:00 – 1:45 pm

主持人：Christine Ambrosone, Roswell Park Comprehensive Cancer Center, Buffalo, New York

Patient Advocate:  Tomika Bryant, King of Prussia, Pennsylvania

补充剂和大麻

Supplements and Cannabis 

Heather Greenlee, Fred Hutchinson Cancer Center, Seattle, Washington 

性健康

Sexual Health 

Don Dizon, Legorreta Cancer Center at Brown University/Lifespan Cancer Institute, Providence, Rhode Island 

治疗期间的运动

Exercise During Treatment

Rikki Cannioto, Roswell Park Comprehensive Cancer Center, Buffalo, New York 

饮食与饮酒

Eating and Drinking 

Lawrence Kushi, Kaiser Permanente Northern California, Pleasanton,California 

• Panel Discussion

地点和时间： Room 221ABC，12月10日 12:00 – 1:45 pm 

主持人：Brenda Ernst, Mayo Clinic Comprehensive Cancer Center, Phoenix, Arizona

联邦资助机会

Federal Funding Opportunities

Larissa Korde, Johns Hopkins School of Medicine, Washington, D.C.

基金会和社区项目支持

Foundation and Community Program Support 

Sara Tolaney, Dana-Farber Cancer Institute, Boston, Massachusetts 

行业互动和资助项目

Industry Interactions and Funding Programs 

Minetta Liu, Natera, Austin, Texas 

• Panel Discussion

地点和时间：Stars at Night 1-2，12月10日 2:00 – 3:45 pm

主持人：Mirat Shah, FDA, Silver Springs, Maryland, and Patricia LoRusso, Yale School of Medicine, New Haven, Connecticut

Speakers and Panelists: Stacy Shord, Julia Maues, Mallorie Fiero, and Michael Ignatiadis

Part A: 

为什么是现在？肿瘤学中剂量优化的必要性

Why Now? The Need for Dosage Optimization in Oncology. 

Patricia LoRusso, Yale School of Medicine, New Haven, Connecticut 

剂量优化的细节和基础

The Nuts and Bolts of Dosage Optimization

Stacy Shord, FDA, Silver Springs, Maryland 

什么是方案优化？为什么我们需要它？

What is Regimen Optimization and Why do We Need It 

Mirat Shah, FDA, Silver Springs, Maryland 

现实剂量：患者视角

A Dose of Reality: The Patient Perspective 

Julia Maues, Patient Advocate, Baltimore, Maryland Discussion/Q&A: Everyone 

Part B:

临床试验设计中的交叉缺失

Lack of Crossover in Clinical Trial Design 

Michael Ignatiadis, Institut Jules Bordet, Brussels, Belgium 

• Discussion/Q&A: Everyone

地点和时间：Stars at Night 3-4，12月10日 2:00 – 3:45 pm

主持人：Christine Desmedt, KU Leuven, Leuven, Belgium

多重成像技术在精准肿瘤学中的应用

Multiplex Imaging for Precision Oncology 

Raza Ali, Cancer Research UK, Cambridge, United Kingdom 

单细胞T细胞受体和B细胞受体

Single Cell T-Cell Receptors and B-Cell Receptors

Diether Lambrechts, Catholic University of Leuven, Leuven, Belgium 

空间转录组学

Spatial Transcriptomics 

Christos Sotirou, Institut Jules Bordet, Brussels, Belgium 

癌症免疫学发现方法在临床试验中的应用

Cancer Immunology Discovery Approaches into Clinical Trials 

Emanuela Romano, Institut Curie, Paris, France 

• Panel Discussion

地点和时间：Room 221ABC，12月10日 2:30 – 4:00 pm

主持人：Saranya Chumsri, Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida, and Brenda Ernst, Mayo Clinic Comprehensive Cancer Center, Phoenix, Arizona

Patient Advocate: Debora Denardi, Miami Beach, Florida

临床研究中合作伙伴关系的重要性

Importance of Partnerships in Clinical Research 

Edith Perez, Mayo Clinic, Kenwood, California 

设计以患者为中心的临床试验

Designing Patient-centric Clinical 

Trials Tatiana Prowell, FDA, Silver Spring, Maryland 

新颖的统计设计：将患者放在首位

Novel Statistical Designs: Putting Patients First 

Amylou Dueck, Mayo Clinic Cancer Center, Scottsdale, Arizona

地点和时间：Stars at Night 1-2，12月10日 4:00 – 5:45 pm

主持人：Matteo Lambertini, University of Genova - IRCCS Ospedale Policlinico, San Martino, Genoa, Italy

Patient Advocate: Na'Diah Smith, Dallas, Texas

年轻女性乳腺癌的生物学特征

Biology of Breast Cancer in Young Women 

Camila Dos Santos, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 

卵巢抑制：谁、何时、为何以及持续多久

Ovarian Suppression: Who, When, Why, and for How Long

Prudence Francis, Peter MacCallum Cancer Centre, Melbourne, Australia 

幸存者

Survivorship 

Jennifer Sheng, Johns Hopkins University, Baltimore, Maryland 

• Panel Discussion

地点和时间：Hemisfair Ballroom 1-2，12月10日 4:00 – 5:45 pm

主持人：Adrian Lee, University of Pittsburgh, Pittsburgh, Pennsylvania

Patient Advocate: Ellen Landsberger, New York City, New York

当前技术综述

Review of Current Technologies

Heather Parsons, Dana-Farber Cancer Institute, Boston, Massachusetts 

早期检测与分子复发性疾病

Early Detection and Molecular Recurrent Disease

Ben Park, Vanderbilt University Medical Center, Nashville, Tennessee 

在转移性环境中的效用

Utility in the Metastatic Setting 

David Cescon, UHN Princess Margaret Cancer Centre, Toronto, Canada 

• Panel Discussion

地点和时间：Hemisfair Ballroom 3，12月10日 4:00 – 5:45 pm

主持人：Reuben S. Harris, UT Health San Antonio, San Antonio, Texas

正常乳腺组织中非整倍体上皮细胞的鉴定

Identification of Aneuploid Epithelial Cells in Normal Breast Tissues 

Nicholas Navin, MD Anderson Cancer Center, Houston, Texas 

乳腺癌进展的基因组和微环境决定因素

Genomic and Microenvironment Determinants of Breast Cancer Progression 

Christina Curtis, Stanford University, Stanford, California 

三阴性乳腺癌中的单细胞基因组学

Single Cell Genomics in Triple Negative Breast Cancer

Ashley Laughney, Weill Cornell Medicine, New York, New York 

• Panel Discussion

地点和时间：Stars at Night 3-4，12月10日 4:00 – 5:45 pm

主持人：Javier Cortés, International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain

Patient Advocate: Thelma Brown, Birmingham, Alabama

新辅助管理与适应性策略

Neoadjuvant Management and Adaptive Strategies 

Gabe Sonke, Netherlands Cancer Institute, Amsterdam, Netherlands

早期阶段小肿瘤的治疗

Treatment of Small Tumors in Early-Stage Setting 

Adrienne Waks, Dana-Farber Cancer Institute, Boston, Massachusetts

非pCR患者的新辅助治疗后管理

Post Neoadjuvant Management for non pCR

Joyce O'Shaughnessy, Baylor-Sammons Cancer Center, Dallas, Texas 

• Panel Discussion

地点：Main Lobby

地点和时间：Stars at Night 1-2，12月10日 6:00 – 7:00 pm

主持人：Rita Nanda, University of Chicago Medicine, Chicago, Illinois

可手术乳腺癌患者省略即刻手术或减少手术范围的长期影响：对四项随机试验2,514名女性患者水平的荟萃分析

LB1-01: Long-term effects of the omission of immediate surgery in operable breast cancer, or reduction of surgical extent: patient-level meta-analysis of the four randomised trials among 2,514 women.

Robert Hills, University of Oxford, Oxford, United Kingdom

MARGOT/TBCRC052：一项随机II期试验，比较新辅助紫杉醇/ margetuximab /帕妥珠单抗（TMP）与紫杉醇/曲妥珠单抗/帕妥珠单抗（THP）在II-III期HER2阳性乳腺癌患者中的疗效

LB1-02: MARGOT/TBCRC052: A randomized phase II trial comparing neoadjuvant paclitaxel/margetuximab/pertuzumab (TMP) vs paclitaxel/trastuzumab/pertuzumab (THP) in patients (pts) with stage II-III HER2+ breast cancer.

Adrienne Waks, Dana-Farber Cancer Institute, Boston, Massachusetts

PADMA研究：比较一线ET联合哌柏西利 vs标准单药化疗用于具有化疗指征的高危HER2-/HR+转移性乳腺癌患者随机III期试验主要结果

LB1-03: Primary results of the randomised Phase III trial comparing first-line ET plus palbociclib vs standard mono-chemotherapy in women with high risk HER2-/HR+ metastatic breast cancer and indication for chemotherapy - PADMA study.

Sibylle Loibl, German Cooperative Group, Neu-Isenburg, Germany

DESTINY-Breast06额外分析：根据既往以内分泌治疗为基础的方案疾病进展速度比较德曲妥珠单抗（T-DXd） vs 医生选择的化疗（TPC）的疗效和安全性

LB1-04: Efficacy and safety of trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) by pace of disease progression on prior endocrine-based therapy: additional analysis from DESTINY-Breast06.

Aditya Bardia, UCLA David Geffen School of Medicine, Los Angeles, California

SOLTI VALENTINE主要结果：一项新辅助随机II期试验旨在评估HER3-DXd单药或与来曲唑联合用于高危HR+/HER2-早期乳腺癌（EBC）的疗效

LB1-06: Primary results of SOLTI VALENTINE: neoadjuvant randomized phase II trial of HER3-DXd alone or in combination with letrozole for high-risk hormone receptor positive (HR+)/HER2-negative (neg) early breast cancer (EBC).

Mafalda Oliveira, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

帕博利珠单抗或安慰剂+化疗新辅助治疗，后帕博利珠单抗或安慰剂辅助治疗用于早期三阴性乳腺癌：III期KEYNOTE-522研究探索性生物标志物分析

LB1-07: Exploratory Biomarker Analysis of the Phase 3 KEYNOTE-522 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage TNBC.

Joyce  O’Shaughnessy, Baylor-Sammons Cancer Center, Dallas, Texas

本文整理自SABCS官网公布的信息，不代表名单为实际现场参会专家。若有任何遗漏或错误，可联系我们进行修改。